Prescient Therapeutics targets $7 million raise to advance PTX-100 cancer program
Prescient Therapeutics Ltd (ASX:PTX) is seeking to raise up to $7 million through a Share Purchase...
Prescient Therapeutics Ltd (ASX:PTX) is seeking to raise up to $7 million through a Share Purchase...
Experienced oncology drug development executive Dr Rosalind Wilson is joining Prescient Therapeutics Ltd (ASX:PTX) as chief medical...
Prescient Therapeutics Ltd (ASX:PTX) has highlighted continued progress across its oncology development pipeline during the...
Prescient Therapeutics Ltd (ASX:PTX) is advancing enrolment in its Phase 2 clinical trial for lead asset...
Cancer remains one of the most formidable challenges in modern medicine — but it is...
Prescient Therapeutics Ltd (ASX: PTX) reported meaningful regulatory progress during the December 2025 quarter, with...
Prescient Therapeutics CEO James McDonnell talked with Proactive about the company’s clinical and regulatory progress...
Prescient Therapeutics Ltd (ASX: PTX) earlier this week received European authorisation to begin clinical trials...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) on Wednesday issued results for the June quarter highlighting the first...
In a sector where the right drug emerging at the right time can yield billions, Prescient...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.